{"AlternateComparison":false,"RelatedProducts":false,"Specification":true,"FeatureBenefit":false}
BD® 유해약물(HD) 체크 시스템

BD® HD Check System Collection Kit

Icon to close the modal
지원
Becton, Dickinson and Company
전화 아이콘
(82.2) 080-340-3800
bd_korea@bd.com
모달 닫기 아이콘
감사 모달 닫기 아이콘
영업팀에 연락해 주셔서 감사합니다!
영업 담당자가 곧 연락을 드립니다.
Address
위치 아이콘
Becton Dickinson Korea Co., Ltd. 한국 서울특별시 강남구 테헤란로 142 아크플레이스 16층 06236
Overview

운송, 준비, 투여 또는 폐기물 처리 중에 유해 약물(HD)을 취급하는 사람은 누구나 위험에 노출될 수 있습니다. 캐나다의 6개 병원을 대상으로 한 연구에 따르면 병원 투약 시스템의 모든 단계에서 자주 접촉하는 표면에 측정 가능한 수준의 항종양 약물 오염이 발견되었습니다.9


혁신적인 BD® HD Check System 편리한 휴대용 설계로 어느 위치에서나 특정 HD를 테스트할 수 있습니다. 10분 이내에 신뢰할 수 있고 읽기 쉬운 결과를 제공하므로 즉각적인 시정 조치를 취하고 HD 잔여물이 확산되는 것을 방지할 수 있습니다. 

방법 보기 >

true
Features and Benefits
Promotional Story
false
Specification

GTIN - Each

00382905150333

1

GTIN - Case

50382905150338

20

GTIN - Shelfpack

30382905150334

10


Case Quantity

20

GTIN

GTIN - Each 00382905150333 1
GTIN - Case 50382905150338 20
GTIN - Shelfpack 30382905150334 10

Packaging

Case Quantity 20
Electronic Instructions for Use (eIFUs)
Resources
Frequently Asked Questions
false
Related Products
RELATED PRODUCTS NOT AVAILABLE
References
  1. Hazardous drug exposures in healthcare. Centers for Disease Control and Prevention website. www.cdc.gov/niosh/topics/hazdrug/. Published September 27, 2018. Accessed December 2, 2019.
  2. Cavallo D, Ursini CL, Perniconi B, et al. Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res. 2005;587(1-2):45–51.
  3. McDiarmid MA, Oliver MS, Roth TS, Rogers B, Escalante C. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med. 2010;52(10):1028– 34.
  4. Skov T, Maarup B, Olsen J, et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992;49(12):855–861.
  5. Hansen J, Olsen JH. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health. 1994;20(1):22–26.
  6. Sotaniemi EA, Sutinen S, Arranto AJ, et al. Liver damage in nurses handling cytostatic agents. Acta Med Scand. 1983;214(3):181–189.
  7. Nurses’ Health and Workplace Exposures to Hazardous Substances. Study conducted by Environmental Working Group, Health Care Without Harm, American Nurses Association, Environmental Health Education Center at University of Maryland School of Nursing. Environmental Working Group website. http://www.ewg.org/research/nurseshealth/nurses-exposure Published December 11, 2007. Accessed January 24, 2017.
  8. Hemminki K, Kyronen P, Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985; 39(2): 141–147.
  9. Hon CY, Teschke K, Chu W, Demers P, Venners S. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. J Occup Environ Hyg. 2013;10(7):374-83. doi: 10.1080/15459624.2013.789743.
  10. Connor TH, Zock MD, Snow AH. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations. J Occup Environ Hyg. 2016;13(9):658-687. doi: 1080/15459624.2016.1165912.
  11. Gabay M, Johnson P, Fanikos J, et al. Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination. Am J Health Syst Pharm. 2021;78(17):1568-1575. doi:10.1093/ajhp/zxab134
  12. Valero-García S, González-Haba E, Gorgas-Torner MQ, et al. Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH). Farm Hosp. 2021;45(2):96-107. doi:10.7399/fh.11655
  13. Domingo T, Fontán G, Enríquez M, et al. Guide for monitoring surfaces for hazardous drug contamination. 1st ed. Instituto Español de Investigación Enfermera; Consejo General de Enfermería; 2021.
  14. Valero García S, Centelles-Oria M, Palanques-Pastor T, Vila Clérigues N, López-Briz E, Poveda Andrés JL. Analysis of chemical contamination by hazardous drugs with BD HD Check® system in a tertiary hospital. J Oncol Pharm Pract. 2021;10781552211038518. doi: 10.1177/ 10781552211038518
  15. Kiffmeyer TK, Tuerk J, Hahn M, et al. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies–the MEWIP project. Ann Occup Hyg. 2013;57(4):444–455. doi:10.1093/annhyg/mes081.
  16. Salch SA, Zamboni WC, Zamboni BA, Eckel SF. Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies. Am J Health Syst Pharm. 2019;76(9):591-598. doi:10.1093/ajhp/zxz033
  17. United States Pharmacopeial Convention (USP). USP general chapter <800>. Hazardous drugs – handling in healthcare settings. Rockville, MD: United States Pharmacopeial Convention. DocID: GUID-5D76173F-5CB6-47B8-815E-7C275A916085_7_en-US
  18. Wipe Analysis. Pharmacy Purchasing & Products. https://www.pppmag.com/article/2525. Published March 2020. Accessed May 21, 2021.
  19. Massoomi F. HD Check-In An interview with HD safety expert Fred Massoomi, RPh, PharmD, FASHP. BD-7875. 2018.


BD-5894 (09/22)

true
true